The new license will allow the pharmaceutical company to deploy the technology broadly throughout its organization and provide for long-term access.
As a part of the agreement, the licensee will make a pre-delivery payment and a post-delivery payment in return for long-term non-exclusive rights to utilize the technology for therapeutic antibody discovery.
Ablexis chief executive officer Larry Green said the Ablexis team will make the AlivaMab Mouse platform available for antibody drug discovery through flexible partnering strategies.
"Ablexis looks forward to establishing additional partnerships to satisfy the biopharmaceutical industry’s need for robust antibody drug discovery platforms," Green added.
AlivaMab Mouse is a next-generation transgenic mouse platform intended to enable the efficient discovery and development of the next generation of human therapeutic antibodies.